Merck & Co., Inc. stands to expand its lead among PD-1 and PD-L1 checkpoint inhibitors in cancers affecting women with new interim Phase III results for Keytruda (pembrolizumab) in newly diagnosed, high-risk locally advanced cervical cancer, given the checkpoint inhibitor’s existing approvals in cervical cancer indications as well as in other gynecological cancers.
Without disclosing data, Merck announced on 19 July that in the KEYNOTE-A18 trial, Keytruda combined with external beam radiotherapy (EBRT)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?